Empowering researchers to spatially profile more than 500 proteins simultaneously in FFPE tissue using abcam’s IHC-validated immuno-oncology antibody portfolio

NanoString Technologies (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, announced today the launch of the latest assay for the GeoMx® Digital Spatial Profiler (DSP). The GeoMx IO Proteome Atlas (IPA) is the industry’s most comprehensive spatial proteomics assay, enabling spatial profiling of more than 500 immuno-oncology (IO) relevant targets from FFPE (Formalin-Fixed, Paraffin-Embedded) tissue sections.

Containing IHC-compatible antibodies entirely from abcam’s extensive IO portfolio, the GeoMx IPA provides an extraordinary advancement in the field of spatial proteomics. The assay will provide researchers with more than five times the content of any competing panel, offering access to unprecedented power. Its utility is applicable to the search for novel biomarkers and drug targets, investigating therapeutic response, stratifying patients, and determining drug mechanisms of action.

“The GeoMx IPA represents the convergence of two of the most dynamic fields in biomedical research: spatial biology and high-plex proteomics,” said Brad Gray, President and CEO of NanoString. “And with abcam providing the content, users get access to a broad range of high-quality recombinant IO antibodies in a single assay. When the IO Proteome Atlas is used in combination with our popular Whole Transcriptome Atlas (WTA), GeoMx DSP becomes by far the most powerful spatial profiler available.”

The combination of NanoString’s GeoMx IPA and WTA offers researchers unprecedented levels of data in the largest ever spatial proteomic panel of its kind. The panel leverages the unique capabilities of GeoMx DSP to non-destructively and quantitatively profile protein expression over five logs of dynamic range in distinct compartments such as the tumor, stroma, and immune contexture. Researchers can run GeoMx IPA as a standalone assay or in conjunction with GeoMx WTA and can even layer GeoMx IPA data with previously collected WTA data to easily analyze the two datasets.

“We are excited to partner with NanoString on this first-of-its-kind assay for high-plex spatial proteomics of FFPE,” said Alejandra Solache, SVP, R&D at abcam. “By contributing to the GeoMx IO Proteome Atlas we’re able to make abcam’s broad portfolio of precision antibodies for IO research available to researchers in a cutting-edge spatial biology product that will help enhance our understanding of cancer immunology and accelerate novel discoveries.”

The launch of the GeoMx IPA is the latest development in a long-standing collaboration between NanoString and abcam to provide high-quality, validated antibodies for use with NanoString’s spatial analysis platforms. Most recently, NanoString and abcam announced the inclusion of abcam-validated antibodies in the first 64-plex panel for NanoString’s CosMx™ Spatial Molecular Imager.

Although the content is targeted for IO research, GeoMx IPA has broad applicability beyond cancer, including research areas such as infectious disease, organ transplant, autoimmunity, metabolism, and epigenetics.

The GeoMx IPA assay can enable researchers to:

• Spatially profile FFPE tissue using over 500 of abcam’s IHC-validated IO antibodies in a single assay, simplifying the search for new protein biomarkers and drug targets with unrivaled plex. Antibodies can also be used individually for further single target or lower plex investigation.
• Obtain more comprehensive biological information from precious tissue samples than traditional immunohistochemistry (IHC) or immunofluorescence (IF) assays.
• Discover novel IO drug targets by profiling the expression of over 500 protein targets from a single FFPE tissue section.
• Profile the whole human transcriptome and IO proteome from a single slide by combining GeoMx IPA with GeoMx WTA for same-slide spatial proteogenomic analysis.

The GeoMx IPA assay is available now for pre-order with shipments expected to begin in Q4 2023.

About NanoString Technologies, Inc.

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics. The CosMx™ Spatial Molecular Imager is a single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. For more information, visit www.nanostring.com.

The NanoString logo, NanoString, NanoString Technologies, GeoMx, CosMx and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc., in the United States and/or other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230913107981/en/